Clinical Trial Update: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial update investigates neoadjuvant endocrine therapy combined with palbociclib and avelumab for estrogen receptor-positive breast cancer. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BAVENCIO (AVELUMAB)
• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING